Results 1 to 10 of about 10,403 (155)

Association of polymorphism of CYP2D6 and CYP2C9 genes encoding P-450 proteins of cytochrome with arterial hypertension [PDF]

Саратовский научно-медицинский журнал, 2012
Gene polymorphisms of cytochrome P-450 CYP2 encoding proteins of cytochrome P-450 are essential forantihy-pertensive drugs metabolism. Purpose: We study the associations of functionally defective allele variants of CYP2D6 gene and CYP2C9 gene with the ...
Saratsev A.V., Posnenkova O.M., Reshetko O.V., Kiselev A.R., Bychkov E.N., Shevchenko O.V., Borodulin V.B., Losev O.E.   +7 more
doaj   +3 more sources

Determinants of the substrate specificity of human cytochrome P-450 CYP2D6: design and construction of a mutant with testosterone hydroxylase activity [PDF]

Biochemical Journal, 1998
Cytochrome P-450 CYP2D6, human debrisoquine hydroxylase, metabolizes more than 30 prescribed drugs, the vast majority of which are small molecules containing a basic nitrogen atom. In contrast, the similar mouse protein Cyp2d-9 was first characterized as a testosterone 16α-hydroxylase. No common substrates have been reported for the two enzymes.
Smith, Gillian, Modi, Sandeep, Pillai, Ilona, Lian, Lu-Yun, Sutcliffe, Michael J., Pritchard, Michael P., Friedberg, Thomas, Roberts, Gordon C. K., Wolf, C. Roland   +8 more
openaire   +5 more sources

Cytochrome P-450 2D6 (CYP2D6) Genotype and Breast Cancer Recurrence in Tamoxifen-Treated Patients: Evaluating the Importance of Loss of Heterozygosity [PDF]

American Journal of Epidemiology, 2016
Tamoxifen therapy for estrogen receptor-positive breast cancer reduces the risk of recurrence by approximately one-half. Cytochrome P-450 2D6, encoded by the polymorphic cytochrome P-450 2D6 gene (CYP2D6), oxidizes tamoxifen to its most active metabolites.
Ahern, Thomas P, Hertz, Daniel L, Damkier, Per, Ejlertsen, Bent, Hamilton-Dutoit, Stephen J, Rae, James M, Regan, Meredith M, Thompson, Alastair M, Lash, Timothy, Cronin-Fenton, Deirdre P   +9 more
openaire   +4 more sources

Influence of amino acid residue 374 of cytochrome P-450 2D6 (CYP2D6) on the regio- and enantio-selective metabolism of metoprolol [PDF]

Biochemical Journal, 1996
Cytochrome P-450 2D6 (CYP2D6) is an important human drug-metabolizing enzyme responsible for the oxidation of more than 30 widely used therapeutic agents. The enzymes encoded by the published genomic [Kimura, Umeno, Skoda, Meyer and Gonzalez (1989) Am. J. Hum. Genet.
M. J. Ackland, Eleni A. Rekka, C R Wolf, K Rowland, S W Ellis, Geoffrey T. Tucker, Anthony P. Simula, Martin S. Lennard   +7 more
openaire   +3 more sources

Impact of CYP2D6, MAOA, and UGT2B7 genetic variants on recurrence of Plasmodium Vivax in the Brazilian Amazon [PDF]

Scientific Reports
The biotransformation of primaquine is mediated by cytochrome P-450 (CYP) enzymes and monoamine oxygenase A (MAO-A). Polymorphisms in the genes that encode these enzymes can alter the clinical response of patients with Plasmodium vivax malaria, leading ...
Gabrielly S. da Silva, Flávia A. Fontenelle, Amanda O. Carvalho, Marielle M. Macêdo, Manuela C. Morais, Rebeca L. Abreu Netto, Victor I. Mwangi, Maria G. C. Alecrim, Marcus V. G. Lacerda, Fernanda Rodrigues-Soares, Anne C. G. de Almeida, Gisely Cardoso de Melo   +11 more
doaj   +2 more sources

Arg296 to Cys296 polymorphism in exon 6 of cytochrome P-450-2D6 (CYP2D6) is not associated with multiple system atrophy. [PDF]

Journal of Neurology, Neurosurgery & Psychiatry, 1995
Niall Quinn, Oliver Bandmann, Gregor K. Wenning, A E Harding   +3 more
openaire   +4 more sources

Association of cytochrome P-450 n D6(CYP2D6) gene polymorphism with some diseases.

Japanese Journal of Pharmacology, 1993
Yutaka Tsuneoka, Yoshiyuki Ichikawa, Yoshinori Matsuo   +2 more
openaire   +3 more sources

Variability Between Clinical Pharmacogenetics Implementation Consortium (CPIC®) Guidelines and a Commercial Pharmacogenetics Laboratory in Genotype to Phenotype Interpretations For Patients Utilizing Psychotropics

Frontiers in Pharmacology, 2022
Clinical practice environments without in-house pharmacogenetic testing often rely on commercial laboratories, especially in the setting of pharmacogenetic testing intended to guide psychotropic use.
Christopher Blazy, Vicki Ellingrod, Kristen Ward, Kristen Ward   +3 more
doaj   +1 more source

Variation in Human Cytochrome P-450 Drug-Metabolism Genes: A Gateway to the Understanding of Plasmodium vivax Relapses. [PDF]

PLoS ONE, 2016
Although Plasmodium vivax relapses are classically associated with hypnozoite activation, it has been proposed that a proportion of these cases are due to primaquine (PQ) treatment failure caused by polymorphisms in cytochrome P-450 2D6 (CYP2D6).
Ana Carolina Rios Silvino, Gabriel Luiz Costa, Flávia Carolina Faustino de Araújo, David Benjamin Ascher, Douglas Eduardo Valente Pires, Cor Jesus Fernandes Fontes, Luzia Helena Carvalho, Cristiana Ferreira Alves de Brito, Tais Nobrega Sousa   +8 more
doaj   +1 more source

Impact of amiodarone use on metoprolol concentrations, α‐OH‐metoprolol concentrations, metoprolol dosing and heart rate: A cross‐sectional study

Pharmacology Research & Perspectives, 2023
Small studies suggest that amiodarone is a weak inhibitor of cytochrome P450 (CYP) 2D6. Inhibition of CYP2D6 leads to increases in concentrations of drugs metabolized by the enzyme, such as metoprolol. Considering that both metoprolol and amiodarone have
Sabrina Robert, Marc‐Olivier Pilon, Essaïd Oussaïd, Maxime Meloche, Grégoire Leclair, Martin Jutras, Marie‐Josée Gaulin, Ian Mongrain, David Busseuil, Jean‐Claude Tardif, Marie‐Pierre Dubé, Simon deDenus   +11 more
doaj   +1 more source